URMC First in Nation to Implant Heart Failure Device That Offers Glimpse of Personalized Medicine

Jun 17, 2010
URMC First in Nation to Implant Heart Failure Device That Offers Glimpse of Personalized Medicine

(PhysOrg.com) -- Cardiologists at the University of Rochester Medical Center are the first to enroll in a clinical trial for an investigational management system for congestive heart failure patients. The technology will help patients and their doctors more closely monitor heart health status on a daily basis and potentially could impact the progression of heart failure.

The LAPTOP-HF trial (Left Atrial Pressure Monitoring to Optimize Therapy), sponsored by St. Jude Medical, is a pivotal, randomized, controlled, prospective, multi-center clinical investigation to evaluate the safety and effectiveness of the company’s implantable left atrial pressure (LAP) heart failure management system. The system is being studied under an investigational device exemption from the U.S. . Currently, there is no other means of obtaining left atrial pressure measurements outside the clinic or hospital setting.

The technology aims to direct therapy in a more timely manner and prevent episodes of worsening heart failure, potentially improving symptoms and reducing the need for repeat hospitalization.The system includes:

• A small, pacemaker-size, stand-alone, implantable LAP monitoring device, or a cardiac rhythm management (CRT/ICD) device with an integrated LAP monitoring device;

• A lead, or thin wire from the device to the heart, with an LAP sensor, called the HeartPOD

• Patient Advisor Module (PAM), a portable, wireless, hand-held device used by the patient to check LAP status and, through the DynamicRx feature, directs the patient to take specific medicines or make lifestyle adjustments based on the LAP measurement.

This video is not supported by your browser at this time.

Cardiac electrophysiologist Spencer Z. Rosero, M.D., associate professor of Medicine at URMC and director of the of the Hereditary Arrhythmia Clinic, and transplant cardiologist Leway Chen, M.D., M.P.H., associate professor of Medicine and director of the Program in Heart Failure and Transplantation, are leading the study in Rochester.

The pivotal trial is expected to enroll about 700 patients at up to 75 centers across the United States. URMC was the first center in the nation to implant the technology, in September, as part of a feasibility trial and is also the first center to participate in this current phase of the study.

Study volunteers will consist of New York Heart Association (NYHA) Class III patients with a history of ischemic or non-ischemic cardiomyopathy for at least six months and at least one heart failure hospitalization within the past 12 months. They are randomized to a treatment group that receives the implantable sensor along with the hand-held device that wirelessly collects data from the LAP sensor and provides that information as well as medication recommendations from their physician directly to the patient, or to a control group that receives standard heart failure therapy.

Currently, physicians’ care decisions are guided primarily by patient-reported symptoms such as breathlessness, reduced exercise capacity, swelling of the ankles, fatigue and weakness. Using these red flags, a diagnosis can be made regarding worsening heart failure and can, for instance, prompt a change in medication dosage. Often, though, by the time symptoms become obvious, the patient needs to be hospitalized.

The investigational St. Jude Medical technology could allow patients and physicians to become aware earlier of subtle changes in the body and spur treatment changes before symptoms begin or become more serious

“This technology, if it proves to be effective in clinical trials, could eventually improve patients’ quality of life by potentially keeping them healthier and out of the hospital,” Rosero said. “This approach is clearly proactive and is an important step toward personalized health monitoring that focuses on providing patients themselves with real-time information and control over their care.”

Physician-directed, patient self-management, which has become standard in diabetes management, is a new approach for heart failure management. It is intended to provide physicians with the ability to better personalize and optimize heart failure management using daily, objective measures of a patient’s status. By providing patients with daily feedback on their left atrial pressure status and associated prescription instructions, it may also encourage self-management and treatment adherence.

“Being able to monitor a patient’s health on a daily basis, in real time, can help us catch subtle physiological changes and adjust treatment to address them, before long-term effects impact heart failure,” Chen said. “And for patients, this truly empowers them, giving them more control over their health.”

Explore further: Experts call for higher exam pass marks to close performance gap between international and UK medical graduates

add to favorites email to friend print save as pdf

Related Stories

New heart failure device is tested

Oct 17, 2006

Physicians at 50 U.S. medical facilities are taking part in a multinational clinical trial of a device designed to help heart failure victims.

New therapy found to prevent heart failure

Jun 23, 2009

A landmark study has successfully demonstrated a 29 percent reduction in heart failure or death in patients with heart disease who received an implanted cardiac resynchronization therapy device with defibrillator (CRT-D) ...

New Clinical Trial Studies Heart Failure Therapy

May 13, 2010

(PhysOrg.com) -- A new clinical trial at UC Health University Hospital is looking at how cardiac resynchronization therapy (CRT) may help individuals with advanced heart failure who may not have been previously ...

Recommended for you

What are the chances that your dad isn't your dad?

Apr 16, 2014

How confident are you that the man you call dad is really your biological father? If you believe some of the most commonly-quoted figures, you could be forgiven for not being very confident at all. But how ...

New technology that is revealing the science of chewing

Apr 15, 2014

CSIRO's 3D mastication modelling, demonstrated for the first time in Melbourne today, is starting to provide researchers with new understanding of how to reduce salt, sugar and fat in food products, as well ...

After skin cancer, removable model replaces real ear

Apr 11, 2014

(HealthDay)—During his 10-year struggle with basal cell carcinoma, Henry Fiorentini emerged minus his right ear, and minus the hearing that goes with it. The good news: Today, the 56-year-old IT programmer ...

User comments : 0

More news stories

Leeches help save woman's ear after pit bull mauling

(HealthDay)—A pit bull attack in July 2013 left a 19-year-old woman with her left ear ripped from her head, leaving an open wound. After preserving the ear, the surgical team started with a reconnection ...

Male monkey filmed caring for dying mate (w/ Video)

(Phys.org) —The incident was captured by Dr Bruna Bezerra and colleagues in the Atlantic Forest in the Northeast of Brazil.  Dr Bezerra is a Research Associate at the University of Bristol and a Professor ...

Scientists tether lionfish to Cayman reefs

Research done by U.S. scientists in the Cayman Islands suggests that native predators can be trained to gobble up invasive lionfish that colonize regional reefs and voraciously prey on juvenile marine creatures.